Rare Disease Trial, Recruiting (NCT06541652)

Rare Disease Trial, Recruiting NCT06541652 Sponsor: Federation Francophone de Cancerologie Digestive Condition: Rare Disease

Printed from Voxsanity (voxsanity.com.au) — NCT06541652 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Rare Disease

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You are 18 years of age or older
You have been diagnosed with one of the following rare liver cancers, confirmed by a tissue sample (biopsy): hepato-cholangiocarcinoma, fibrolamellar hepatocellular carcinoma, epithelioid hemangioendothelioma, or hepatic angiosarcoma
Your diagnosis was made on or after January 1, 2018 (this applies whether you are currently alive or, in some cases, deceased patients may be registered by others)
If you are alive and have not objected to taking part in research, you will need to provide a signed form agreeing to participate in additional studies involving biological samples (such as blood or tissue)

Who may not be able to join:

You do not have social security coverage (health insurance/social coverage in France) (confirm with trial site)
A stored sample of your tumor tissue (called a tumor block) is not available

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: jean-charles nault, Pr, Federation Francophone de Cancerologie Digestive

Phone: 06 99 78 84 73

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06541652

Sponsor: Federation Francophone de Cancerologie Digestive

Phase: Not Applicable

Status: Recruiting

Condition: Rare Disease

Trial contact: 06 99 78 84 73

More information: https://clinicaltrials.gov/study/NCT06541652

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You are 18 years of age or older
You have been diagnosed with one of the following rare liver cancers, confirmed by a tissue sample (biopsy): hepato-cholangiocarcinoma, fibrolamellar hepatocellular carcinoma, epithelioid hemangioendothelioma, or hepatic angiosarcoma
Your diagnosis was made on or after January 1, 2018 (this applies whether you are currently alive or, in some cases, deceased patients may be registered by others)
If you are alive and have not objected to taking part in research, you will need to provide a signed form agreeing to participate in additional studies involving biological samples (such as blood or tissue)

Who may not be able to join:

You do not have social security coverage (health insurance/social coverage in France) (confirm with trial site)
A stored sample of your tumor tissue (called a tumor block) is not available

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Federation Francophone de Cancerologie Digestive

Registry

ClinicalTrials.gov

Start date

26 March 2024

Est. completion

1 February 2026

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Description of the clinical, histological and radiological characteristics of various rare primary liver cancers

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov